FLOW: Semaglutide for Diabetes and Kidney Disease

Here, I provide a brief summary of the FLOW study on semaglutide’s effects in patients with type 2 diabetes and chronic kidney disease. This study highlights the benefits of semaglutide in reducing the risks of kidney failure, cardiovascular events, and death. We will delve into the key findings and results published in the New England Journal of Medicine in May 2024.

STEP: Heart Failure in Obesity & Diabetes

Semaglutide benefits obesity-related heart failure in type 2 diabetes, improving symptoms and aiding weight loss. The STEP trial evaluated the effects of semaglutide (Ozempic or Wegovy) 2.4 mg weekly in participants with heart failure, obesity, and type 2 diabetes. Patients received either semaglutide or placebo for 52 weeks.

SELECT: Obesity & Heart Health

Semaglutide, marketed as Ozempic or Wegovy and administered at a weekly dosage of 2.4 mg, has demonstrated a noteworthy reduction in cardiovascular events by 20% among non-diabetic individuals with obesity. Most participants had a diagnosis of prediabetes and a history of either myocardial infarction (MI) or stroke at the beginning of the study.

How Long Do Weight Loss Injections Last in Rockville, Maryland?

While brands like Wegovy or Ozempic are known for their effectiveness, just how long do weight loss injections last in Rockville, Maryland?